Prelude Capital Management’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-6,886
| Closed | -$1.19M | – | 1291 |
|
|
2025
Q4 | $1.19M | Buy |
+6,886
| New | +$1.25M | 0.09% | 257 |
|
|
2025
Q2 | – | Sell |
-1,514
| Closed | -$256K | – | 1079 |
|
|
2025
Q1 | $256K | Buy |
+1,514
| New | +$249K | 0.02% | 783 |
|
|
2021
Q4 | – | Sell |
-3,434
| Closed | -$499K | – | 2016 |
|
|
2021
Q3 | $499K | Buy |
+3,434
| New | +$502K | 0.01% | 895 |
|
|
2021
Q1 | – | Sell |
-6,885
| Closed | -$820K | – | 1598 |
|
|
2020
Q4 | $820K | Buy |
6,885
+1,358
| +25% | +$166K | 0.02% | 543 |
|
|
2020
Q3 | $633K | Buy |
5,527
+1,411
| +34% | +$167K | 0.03% | 380 |
|
|
2020
Q2 | $469K | Buy |
4,116
+3,980
| +2,926% | +$422K | 0.03% | 486 |
|
|
2020
Q1 | $11K | Buy |
+136
| New | +$14.1K | ﹤0.01% | 1114 |
|
|
2018
Q3 | – | Sell |
-17,960
| Closed | -$1.98M | – | 1787 |
|
|
2018
Q2 | $1.98M | Sell |
17,960
-4,371
| -20% | -$455K | 0.13% | 162 |
|
|
2018
Q1 | $2.24M | Sell |
22,331
-15,620
| -41% | -$1.6M | 0.16% | 100 |
|
|
2017
Q4 | $3.74M | Buy |
37,951
+16,862
| +80% | +$1.6M | 0.3% | 64 |
|
|
2017
Q3 | $1.98M | Buy |
21,089
+941
| +5% | +$99.9K | 0.18% | 122 |
|
|
2017
Q2 | $2.24M | Sell |
20,148
-3,068
| -13% | -$324K | 0.21% | 99 |
|
|
2017
Q1 | $2.28M | Buy |
23,216
+4,734
| +26% | +$451K | 0.22% | 111 |
|
|
2016
Q4 | $1.7M | Buy |
18,482
+10,987
| +147% | +$947K | 0.21% | 131 |
|
|
2016
Q3 | $634K | Buy |
+7,495
| New | +$629K | 0.07% | 271 |
|
|
2016
Q2 | – | Sell |
-944
| Closed | -$67K | – | 1604 |
|
|
2016
Q1 | $67K | Buy |
944
+894
| +1,788% | +$60K | 0.01% | 885 |
|
|
2015
Q4 | $4K | Buy |
+50
| New | +$3.36K | ﹤0.01% | 1343 |
|
|
2015
Q2 | – | Sell |
-40,508
| Closed | -$3.11M | – | 1769 |
|
|
2015
Q1 | $3.11M | Buy |
+40,508
| New | +$2.9M | 0.43% | 29 |
|
|
2014
Q4 | – | Sell |
-1,368
| Closed | -$83K | – | 1953 |
|
|
2014
Q3 | $83K | Buy |
1,368
+305
| +29% | +$18.8K | 0.01% | 1167 |
|
|
2014
Q2 | $62K | Sell |
1,063
-1,019
| -49% | -$59.7K | 0.01% | 1283 |
|
|
2014
Q1 | $121K | Buy |
+2,082
| New | +$112K | 0.02% | 955 |
|
|
2013
Q4 | – | Sell |
-40
| Closed | -$2K | – | 1675 |
|
|
2013
Q3 | $2K | Buy |
+40
| New | +$2.39K | ﹤0.01% | 1665 |
|
Other funds holding DGX
EIG
Prelude Capital Management's DGX Position: Q1 2026 in Review
Prelude Capital Management sold out of Quest Diagnostics (DGX) in Q1 2026, closing a stake of 6,886 shares — an estimated $1.19M sold.
Prelude Capital Management first reported a position in DGX in Q3 2013 and held it in 22 quarters. The position peaked at $3.74M in Q4 2017. 1,069 funds tracked by Wall St. Rank hold DGX as of Q1 2026.
- Prelude Capital Management reported no remaining Quest Diagnostics position as of Q1 2026 after selling out during the quarter.
- Prelude Capital Management sold 6,886 Quest Diagnostics shares in Q1 2026, an estimated $1.19M.
- Prelude Capital Management first reported a position in Quest Diagnostics in Q3 2013 and held it in 22 quarters.
- Prelude Capital Management's Quest Diagnostics position peaked at $3.74M in Q4 2017.
- 1,069 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.
Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.